MedTrace Logo

Prospective Study of BMD and Ca-P Metabolism in RSA Patients: LMWH Use Versus Control

NCT05878574 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 344

Last updated 2023-05-26

No results posted yet for this study

Summary

The goal of this prospective observational study is to learn about the effect of low molecular weight heparin (LMWH) application on bone mineral density (BMD) and on calcium-phosphorus metabolism in patients with recurrent spontaneous abortion (RSA), and to compare the degree of bone loss and changes in blood calcium and phosphorus in RSA patients and in control groups with normal pregnancy. By monitoring ultrasound BMD and serum indicators related to maternal bone formation and Ca-P metabolism, the association mechanism between long-term use of LMWH, maternal Ca-P regulation and bone loss will be constructed, so as to contribute to clinical treatment and lifestyle guidance during pregnancy in RSA patients.

Conditions

  • Recurrent Spontaneous Abortion

Interventions

DRUG

Low molecular weight heparin

Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy

Sponsors & Collaborators

  • Aimin Zhao

    lead OTHER

Principal Investigators

  • Aimin Zhao, MD · RenJi Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-12-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05878574 on ClinicalTrials.gov